Dipchand Nishar Sells 10,660 Shares of Seer (NASDAQ:SEER) Stock

Seer, Inc. (NASDAQ:SEER) Director Dipchand Nishar sold 10,660 shares of Seer stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $2.18, for a total value of $23,238.80. Following the completion of the transaction, the director directly owned 59,044 shares in the company, valued at $128,715.92. This trade represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Seer Trading Down 1.4%

Shares of NASDAQ:SEER traded down $0.03 during trading on Friday, reaching $2.17. 300,631 shares of the company traded hands, compared to its average volume of 2,158,689. The firm has a market capitalization of $119.31 million, a price-to-earnings ratio of -1.75 and a beta of 1.59. Seer, Inc. has a 52-week low of $1.55 and a 52-week high of $2.41. The business’s fifty day moving average is $1.81 and its 200-day moving average is $1.84.

Seer (NASDAQ:SEER) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.30). Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%. The firm had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $3.60 million.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. TD Cowen raised shares of Seer to a “strong-buy” rating in a research note on Monday, April 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a report on Tuesday, April 21st. Finally, Canaccord Genuity Group initiated coverage on Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $4.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Occudo Quantitative Strategies LP purchased a new stake in shares of Seer in the 2nd quarter worth about $25,000. Marshall Wace LLP purchased a new position in shares of Seer during the fourth quarter valued at about $85,000. Quadrature Capital Ltd bought a new position in Seer in the fourth quarter worth about $101,000. Barclays PLC lifted its holdings in Seer by 685.0% in the fourth quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after buying an additional 52,982 shares during the period. Finally, Marquette Asset Management LLC bought a new stake in Seer during the 2nd quarter valued at approximately $103,000. 75.20% of the stock is currently owned by institutional investors.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.